Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kintor PharmaceuticalKNTPF 26 Equity-to-Asset is 0.34 as of Jun. 2026, which is 49% below its 10-year median of 0.67. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Kintor Pharmaceutical ranks worse than 75.99% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kintor Pharmaceutical Equity-to-Asset Related Terms
Kintor Pharmaceutical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kintor Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a Equity-to-Asset of 0.34 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kintor Pharmaceutical and its competitors. This is 49% below median its historical median of 0.67. Over the past decade, Kintor Pharmaceutical's Equity-to-Asset has ranged from 0.34 to 0.90. According to the industry distribution chart, Kintor Pharmaceutical ranks #1076 out of 1416 companies in the Biotechnology industry, placing it in the top 76%.
Is Kintor Pharmaceutical's Equity-to-Asset too high?
Kintor Pharmaceutical's current Equity-to-Asset of 0.34 is 49% below median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. Kintor Pharmaceutical's value of 0.34 is 50% below this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #1076 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #1076 out of 1416 companies for Equity-to-Asset. This places Kintor Pharmaceutical in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Kintor Pharmaceutical's value of 0.34 is 50% below this benchmark. Historically, Kintor Pharmaceutical's own Equity-to-Asset has ranged from 0.34 to 0.90 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 0.68, Kintor Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Equity-to-Asset of 0.34 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Equity-to-Asset is 0.34, which is 49% below median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Equity-to-Asset of 0.34. The current Equity-to-Asset is 0.34, which is 49% below median its 10-year median of 0.67 and 50% below the Biotechnology industry median of 0.68. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Equity-to-Asset is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score
Get the complete analysis for KNTPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
